"Safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus and advanced kidney disease: a large pooled analysis of placebo-controlled clinical trials" by M von Eynatte

Selected Works of Katherine R. Tuttle, MD, FASN, FACP, FNKF

Presentation

Safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus and advanced kidney disease: a large pooled analysis of placebo-controlled clinical trials

Annual Meeting of the Japanese Society of Nephrology (2018)

M von Eynatte
A Levin
M Nangaku
T Kadowaki
Katherine Tuttle, Providence St. Joseph Health
S J Hauske
C Zeller
S Kohler
C Wanner

Disciplines

Endocrinology, Diabetes, and Metabolism and
Nephrology

Publication Date

June, 2018

Location

Niigata City, Niigata, Japan

Comments

Poster

Citation Information

M von Eynatte, A Levin, M Nangaku, T Kadowaki, et al.. "Safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus and advanced kidney disease: a large pooled analysis of placebo-controlled clinical trials" Annual Meeting of the Japanese Society of Nephrology (2018)
Available at: http://works.bepress.com/katherine-tuttle/157/